Tucson News NowPhase 2 Results Show INCIVO® (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype -1 Chronic Hepatitis C Virus and HIV.
For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin.
These analyses further confirm that ribavirin dose reduction should be the primary strategy for managing anemia in patients taking VICTRELIS combination therapy, including cirrhotic patients.
Tucson News NowPhase 2 Results Show INCIVO® (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic Hepatitis C Virus and HIV.
Tucson News NowPhase 2 Results Show INCIVO® (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic Hepatitis C Virus and HIV.
1 conclude that the most effective initial treatment for suitable patients with chronic hepatitis C is the combination of 1.5 ?g/kg per week of peginterferon alfa -2b and ribavirin.
***
The current treatment for HCV infection involves the combination therapy of pegylated interferon (IFN) and ribavirin, which yields long term response in only 50% of the cases.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Feld et al. dwell on the mechanism of action of combination treatment of IFN and ribavirin in HCV infected patients.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Dixit et al. extended the work of Neumann et al. in the sense of explicitly including the action of ribavirin.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Dixit et al. assume that ribavirin (either on its own or in conjunction with IFN) renders a fraction of the newly produced HCV non-infectious.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
The model predicts that ribavirin does not have an impact on the IFN induced ﬁrst phase decline .
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
If the efﬁcacy of IFN is large enough, then the second phase decline is not signiﬁcan tly affected by ribavirin.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
However, if the IFN efﬁcacy is much smaller than 1, then the impact of ribavirin in the second phase decline is more profound. A plausible explanation for this is that a high IFN efﬁcacy re sults in low HCV levels, which in turn reduces the role that ribavirin plays in rendering the virions as non-infectious.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
The model was able to explain why ribavirin enhances the second phase of decline in some cases and not in others .
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Finally, the model incorporates the ef ﬁcacy ρ of ribavirin which renders a fraction of the infectious virions non-infectious, with a death rate c for both these populations.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
One observes that for smaller values of IFN efﬁca cy ǫp, the response (in terms of percentage of cases with stable uninfected steady state) is very sensitive to change in the efﬁcacy ρ of ribavirin.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
***